JPWO2020010092A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020010092A5 JPWO2020010092A5 JP2021522931A JP2021522931A JPWO2020010092A5 JP WO2020010092 A5 JPWO2020010092 A5 JP WO2020010092A5 JP 2021522931 A JP2021522931 A JP 2021522931A JP 2021522931 A JP2021522931 A JP 2021522931A JP WO2020010092 A5 JPWO2020010092 A5 JP WO2020010092A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- substituted
- group
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094148A JP2024116295A (ja) | 2018-07-03 | 2024-06-11 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693768P | 2018-07-03 | 2018-07-03 | |
| US62/693,768 | 2018-07-03 | ||
| US201962861825P | 2019-06-14 | 2019-06-14 | |
| US62/861,825 | 2019-06-14 | ||
| PCT/US2019/040317 WO2020010092A1 (en) | 2018-07-03 | 2019-07-02 | Compounds and compositions for treating conditions associated with sting activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094148A Division JP2024116295A (ja) | 2018-07-03 | 2024-06-11 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529833A JP2021529833A (ja) | 2021-11-04 |
| JP2021529833A5 JP2021529833A5 (https=) | 2022-07-08 |
| JPWO2020010092A5 true JPWO2020010092A5 (https=) | 2022-07-08 |
| JP7566731B2 JP7566731B2 (ja) | 2024-10-15 |
Family
ID=67441650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522931A Active JP7566731B2 (ja) | 2018-07-03 | 2019-07-02 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| JP2024094148A Pending JP2024116295A (ja) | 2018-07-03 | 2024-06-11 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094148A Pending JP2024116295A (ja) | 2018-07-03 | 2024-06-11 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11618749B2 (https=) |
| EP (1) | EP3817820A1 (https=) |
| JP (2) | JP7566731B2 (https=) |
| CN (2) | CN112823036B (https=) |
| MA (1) | MA53095A (https=) |
| TW (1) | TWI873098B (https=) |
| WO (1) | WO2020010092A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| CN112823036B (zh) * | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| MA54753A (fr) * | 2019-01-17 | 2021-11-24 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| US20230092163A1 (en) * | 2019-06-14 | 2023-03-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN114761804A (zh) | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| EP4085061A1 (en) * | 2019-12-31 | 2022-11-09 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021161230A1 (en) * | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| JP6912016B1 (ja) * | 2020-04-10 | 2021-07-28 | 小野薬品工業株式会社 | Ｓｔｉｎｇ作動化合物 |
| EP4134134A4 (en) * | 2020-04-10 | 2023-12-27 | ONO Pharmaceutical Co., Ltd. | STING AGONISTIC COMPOUND |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| EP4247790B1 (en) * | 2020-11-23 | 2024-10-09 | Regor Pharmaceuticals, Inc. | Sting antagonists and uses thereof |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4274826A1 (en) * | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Oxalamide compounds and compositions for treating conditions associated with sting activity |
| JP2024502470A (ja) * | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| US20240101556A1 (en) | 2021-01-08 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| AU2022325543A1 (en) * | 2021-08-11 | 2024-02-15 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| CN115710255B (zh) * | 2021-08-23 | 2025-05-06 | 上海交通大学 | 一类含有苯并杂环取代的脲类衍生物及其制备和用途 |
| CN116789641A (zh) * | 2022-03-17 | 2023-09-22 | 中国科学院上海药物研究所 | 二氢异喹啉类化合物及其医药用途 |
| WO2024032597A1 (zh) * | 2022-08-11 | 2024-02-15 | 杭州中美华东制药有限公司 | 具有sting抑制作用的酰胺类化合物及其药物组合物和用途 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CA3267008A1 (en) * | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| TW202432114A (zh) * | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| TW202432545A (zh) * | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| CN120476113A (zh) * | 2022-12-20 | 2025-08-12 | 杭州中美华东制药有限公司 | 具有sting抑制作用的含肟化合物及其药物组合物和用途 |
| CN116023321B (zh) * | 2022-12-30 | 2024-11-29 | 中国药科大学 | Sting抑制剂前药及其医药用途 |
| CN120794957A (zh) * | 2024-05-14 | 2025-10-17 | 中国药科大学 | 苯并含氮杂环类sting抑制剂及其医药用途 |
| CN121342824A (zh) * | 2024-07-16 | 2026-01-16 | 中国药科大学 | 四氢萘啶类sting抑制剂及其医药用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| WO2003028720A1 (en) | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| AU2003245700A1 (en) * | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JP4751063B2 (ja) | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| BR0314098A (pt) * | 2002-09-05 | 2005-07-19 | Aventis Pharma Sa | Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm |
| PL376789A1 (pl) | 2002-12-12 | 2006-01-09 | Aventis Pharma S.A. | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| US20080255153A1 (en) * | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| AU2012256237B2 (en) | 2011-05-13 | 2017-01-05 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| WO2016049774A1 (en) | 2014-10-03 | 2016-04-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| CA2996681C (en) | 2015-08-27 | 2024-04-09 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy |
| JP2019510802A (ja) * | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| US11452717B2 (en) | 2017-01-10 | 2022-09-27 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof |
| JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| CN109180649B (zh) | 2017-08-18 | 2021-03-12 | 四川百利药业有限责任公司 | 一种含吲哚环的ido抑制剂及其制备方法 |
| WO2019122202A1 (en) | 2017-12-20 | 2019-06-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| EP3556362A1 (en) | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| US20210236466A1 (en) | 2018-07-03 | 2021-08-05 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN112823036B (zh) * | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2020106741A1 (en) | 2018-11-19 | 2020-05-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP3883651A1 (en) | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| MA54753A (fr) | 2019-01-17 | 2021-11-24 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| WO2020191227A1 (en) | 2019-03-20 | 2020-09-24 | Cornell University | Methods for controlling prostaglandin-mediated biological processes |
| WO2020236586A1 (en) | 2019-05-17 | 2020-11-26 | Ifm Due, Inc. | N-hetaryl-squaramide compounds for treating conditions associated with sting activity |
| US20220227760A1 (en) | 2019-05-29 | 2022-07-21 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230092163A1 (en) | 2019-06-14 | 2023-03-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN114761804A (zh) * | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| WO2021067801A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2021067805A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity |
| WO2021067791A1 (en) | 2019-10-03 | 2021-04-08 | Ifm Due, Inc. | Oxalamide compounds and compositions for treating conditions associated with sting activity |
| EP4085061A1 (en) | 2019-12-31 | 2022-11-09 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP7756643B2 (ja) | 2019-12-31 | 2025-10-20 | ノバルティス ファーマ アーゲー | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US20220024919A1 (en) | 2020-07-15 | 2022-01-27 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| PY2157405A (es) | 2020-07-15 | 2022-04-22 | Ifm Due Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting |
| WO2022015938A1 (en) | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4182310A1 (en) | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20220024906A1 (en) | 2020-07-15 | 2022-01-27 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230250106A1 (en) | 2020-07-15 | 2023-08-10 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4182030A1 (en) | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
-
2019
- 2019-07-02 CN CN201980057319.9A patent/CN112823036B/zh active Active
- 2019-07-02 JP JP2021522931A patent/JP7566731B2/ja active Active
- 2019-07-02 TW TW108123334A patent/TWI873098B/zh active
- 2019-07-02 WO PCT/US2019/040317 patent/WO2020010092A1/en not_active Ceased
- 2019-07-02 US US16/460,381 patent/US11618749B2/en active Active
- 2019-07-02 EP EP19745408.5A patent/EP3817820A1/en active Pending
- 2019-07-02 CN CN202411419807.9A patent/CN120004785A/zh active Pending
- 2019-07-02 MA MA053095A patent/MA53095A/fr unknown
-
2023
- 2023-03-01 US US18/116,183 patent/US20240083895A1/en active Pending
-
2024
- 2024-06-11 JP JP2024094148A patent/JP2024116295A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020010092A5 (https=) | ||
| JP2021529833A5 (https=) | ||
| JP2021529834A5 (https=) | ||
| JPWO2020010155A5 (https=) | ||
| CN115925796B (zh) | 一种抗肿瘤化合物及其制备方法和应用 | |
| KR102252925B1 (ko) | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 | |
| JP2021176859A (ja) | 免疫調節剤としての複素環化合物 | |
| JP2022535858A (ja) | 抗ｂ７－ｈ４抗体－薬物コンジュゲート及びその医薬的使用 | |
| WO2017016497A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| KR102460736B1 (ko) | 화학적으로-로킹된 이중특이적 항체 | |
| CN111643676B (zh) | 一种双特异性二聚体、双特异性二聚体-药物偶联物及其应用 | |
| JPWO2021138419A5 (https=) | ||
| WO2023198195A1 (en) | Conjugate comprising toll-like receptor agonist | |
| KR20180100652A (ko) | 크로멘 화합물 및 제2활성제의 조합물 | |
| CN119136840A (zh) | 喜树碱类衍生物及配体-药物偶联物 | |
| JPWO2020106736A5 (https=) | ||
| KR20250162577A (ko) | 캄프토테신 유도체, 약학 조성물 및 이의 제조 방법과 용도 | |
| JPWO2020150439A5 (https=) | ||
| CN113646299A (zh) | 作为前列腺素e2(pge2)受体调节剂的新型n-苄基-2-苯氧基苯甲酰胺衍生物 | |
| JP2021516251A (ja) | 抗ｐｄ−１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| TW202545934A (zh) | 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 | |
| CN116162162B (zh) | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 | |
| US20260092116A1 (en) | B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof | |
| CN114786672A (zh) | 西达本胺(Chidamide)及塞来昔布(Celecoxib)的抗癌组合 | |
| CN119280420B (zh) | 多特异性偶联物及其应用 |